New drug combo aims to shrink tough breast cancer before surgery
NCT ID NCT07351487
Summary
This study is testing a treatment plan for triple-negative breast cancer before surgery. The plan combines standard chemotherapy with two immunotherapy drugs, sintilimab and bevacizumab. The main goal is to see if this combination can completely eliminate the cancer in the breast tissue, which is measured after surgery. Researchers will also track side effects and how long patients remain cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, China
Contact
Conditions
Explore the condition pages connected to this study.